ZENAS BIOPHARMA, INC. — Key Metrics
3 years of history · ending 2025-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-8
Book Value Per Share
$5
Free Cash Flow Per Share
$-4
Cash Per Share
$2
Revenue Per Share
$0
OCF Per Share
$-4
Return on Equity
-136.2%
Return on Assets
-100.2%
Return on Invested Capital
-85.0%
Debt to Equity
0.32
Current Ratio
5.61
Quick Ratio
5.61
Asset Turnover
0.03
R&D / Revenue
1680.6%
SBC / Revenue
263.5%
Capex / Revenue
0.2%
Working Capital
$289M
Net Current Asset Value
$210M
Invested Capital
$321M
OCF / Net Income
0.46
FCF / Net Income
0.46
Accruals Ratio (Sloan)
-53.5%
Net Debt
$-265M
Net Debt / EBITDA
0.69
Interest Coverage
-52.28
Cash Coverage
-23.52
Capex Coverage
-9574.06
Tangible Common Equity
$242M
TCE / Total Assets
63.1%
NOPAT
$-303M
Cash ROIC
-48.4%
WC / Revenue
2885.2%
Capex / D&A
0.32
Reinvestment Rate
0.0%
Asset Growth vs Revenue Growth
-96.3%
Stock Price (FY-end)
$36
Market Cap
$1.62B
P/S Ratio
162.41
P/B Ratio
6.71
P/TB Ratio
6.71
Enterprise Value
$1.36B
EV / Sales
135.96
FCF Yield
-10.6%
Shareholder Yield
-1.6%
R&D Yield
10.3%
Capex Yield
0.0%
Shares Variation (YoY)
238.9%
Beta (5Y)
1.59
Cost of Equity
12.4%
Cost of Debt (after tax)
7.4%
52W High
$43
52W Low
$6
Trailing Return 1Y
269.0%
F-Score (Piotroski)
2.00
Z-Score (Altman)
1.73
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.